Tuesday, October 20, 2026, 11 AM-12 PM ET
Hear experts review the biological and clinical significance of the HER2 expression continuum in breast tissue, providing a clearer understanding of how these variations might impact diagnosis, and discuss the emerging importance of documenting HER2-low and HER2-ultralow categories using a validated IHC assay.
Webinar presenters Keith Wharton, MD, PhD, Global Medical Affairs Leader–Pathology, Roche Diagnostics Solutions, and Hannah Y. Wen, MD, PhD, Director, Breast Pathology Fellowship, Associate Team Leader, Breast Pathology Team, Attending Pathologist, Memorial Sloan Kettering Cancer Center
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Roche.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Thursday, October 29, 2026, 1 PM-2 PM ET
Hear an expert discuss the evolving role of PD-L1 testing in HNSCC and ovarian cancer.
Webinar presenter Georgios Deftereos, MD, Professor of Pathology, Associate Director of the Clinical Cancer Genomics Laboratory, Director of Molecular Cytopathology, University of California, San Francisco
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Agilent.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 3, 2026, 1 PM-2 PM ET
Hear an expert discuss the challenges of detecting NRG1 fusions and how RNA-based testing can support more comprehensive fusion identification in clinical practice.
Webinar presenter Benjamin Weinberg, MD, Associate Professor of Medicine and Attending Physician
specializing in gastrointestinal medical oncology
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Diaceutics.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Monday, November 16, 2026, 12:30 PM-2 PM ET
Hear experts discuss a multidisciplinary approach to oncopathology for HER2
assessments for solid tumors in the absence of a companion diagnostic.
Webinar presenters Funda Meric-Bernstam, MD, Chair, Department of Investigational Cancer Therapeutics Medical Director, Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, and Emina E. Torlakovic, MD, PhD, College of Medicine, University of Saskatchewan, Canadian Biomarker Quality Assurance, Saskatoon, Saskatchewan, Canada, and Carol Cheung, MD, PhD, JD, FRCPC, Deputy Director, Canadian Biomarker Quality, Assurance—Programme canadien d’assurance de la qualité des biomarqueurs
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
July 2021—Sysmex America has added the FDA-cleared XN-10 Automated Hematology Analyzer with Blood Bank mode to its portfolio of hematology solutions. The analyzer supports red blood cell and platelet component testing and provides an automated complete blood count with differential for whole blood samples. The XN blood bank mode is intended for use in blood processing centers for QC release testing of post-processed components.
July 2021—Labcorp and OmniSeq announced the launch of OmniSeq Insight, a pan-cancer, solid tumor test that combines genomic and immune profiling, including tumor mutational burden, microsatellite instability, and immune gene expression, and integrates next-generation sequencing technology.
BD announced that the FDA granted emergency use authorization for its rapid antigen test that can detect SARS-CoV-2, influenza A, and influenza B in a single test. The BD Veritor System for Rapid Detection of SARS-CoV-2 & Flu A+B assay takes about 15 minutes to run on the BD Veritor Plus system and distinguishes between SARS-CoV-2, influenza A, and influenza B by providing definitive positive or negative individual digital display readouts for all three. BD plans to launch the test this summer for the 2021–2022 flu season. The test is intended for individuals who are suspected by a health care provider of having COVID-19, flu A, or flu B within six days of symptom onset.
June 2021—OptraScan launched the OS-Ultra 320 high-speed digital pathology scanner. The OS-Ultra 320 scans a 15- × 15-mm region at 40 × magnification in less than 60 seconds and features no-touch, continuous loading operation. The scanner uses real-time autofocus and offers a resolution of 0.25 μm/pixel. It accepts 25- × 75-mm and 50- × 75-mm slides with slide tolerances of ± 1 mm long, ± 1 mm wide, and ± 0.2 mm thick.
June 2021—Bio-Rad Laboratories launched the Bio-Plex Pro Human IgG SARS-CoV-2 N/RBD/S1/S2 4-Plex Panel, a qualitative multiplex immunoassay kit that detects IgG antibodies against four SARS-CoV-2 antigens in less than three hours.
June 2021—PerkinElmer launched two research use only solutions, PKamp VariantDetect SARS-CoV-2 RT-PCR Assay and the next-generation-sequencing–based Nextflex Variant-Seq SARS-CoV-2 Kit. The PKamp VariantDetect SARS-CoV-2 RT-PCR assay can detect mutations associated with B.1.1.7, B.1.351, and P.1 variants. The Nextflex Variant-Seq SARS-CoV-2 WGS workflow can detect all SARS-CoV-2 genetic changes relative to the strain originally identified in Wuhan, China.
June 2021—AccuTec Blades launched its 2021 histology catalog under the new medical brand name, AccuThrive.
June 2021—Beckman Coulter’s Access SARS-CoV-2 IgG II antibody assay received emergency use authorization from the FDA. The semiquantitative assay measures a patient’s level of antibodies in response to a previous SARS-CoV-2 infection and provides a qualitative and numerical result of antibodies in arbitrary units. It measures IgG antibodies directed to the receptor-binding domain of the spike protein of the coronavirus.
June 2021—Diazyme Laboratories obtained CE-IVD marking for its SARS-CoV-2 neutralizing antibody test, a high-throughput chemiluminescent immunoassay.
June 2021—Biocept announced it will collaborate with Protean BioDiagnostics to research the ability of Biocept’s Target Selector molecular assay to determine EGFR status in non-small cell lung cancer patients.
